STOCK TITAN

NovaBridge Biosciences (NBP) grants options and RSUs to executive

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NovaBridge Biosciences director and Chief Business Development Officer Cao Sean Wuxiong received new equity awards. He was granted 181,290 employee share options to buy Ordinary Shares (via American Depositary Shares) at an exercise price of $1.53 per ADS, expiring on June 22, 2036. These options vest in eight equal quarterly installments only after the 30-trading-day weighted average price of the company’s ADS is at or above $8.00.

He also received 181,280 restricted share units, each representing a contingent right to receive one ADS. These RSUs vest over four years, with one-fourth vesting on September 3, 2026 and the remainder vesting ratably over the following 12 quarters.

Positive

  • None.

Negative

  • None.
Insider Cao Sean Wuxiong
Role Chief Bus. Development Officer
Type Security Shares Price Value
Grant/Award Restricted Share Units 181,280 $0.00 --
Grant/Award 2025 Employee Share Option (right to buy) 181,290 $0.00 --
Holdings After Transaction: Restricted Share Units — 181,280 shares (Direct, null); 2025 Employee Share Option (right to buy) — 181,290 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one American Depositary Shares ("ADS"). Number of underlying securities and exercise price expressed in terms of ADSs. The RSUs shall vest over four years, with one-fourth vesting on September 3, 2026 and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month. The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer. The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$8.00.
Employee share options granted 181,290 options Grant on June 22, 2026 to Cao Sean Wuxiong
Option exercise price $1.53 per ADS Exercise price for 2025 Employee Share Option grant
Option expiration June 22, 2036 Expiration date for granted employee options
RSUs granted 181,280 RSUs Grant on June 22, 2026 to Cao Sean Wuxiong
RSU initial vest date September 3, 2026 One-fourth of RSUs vest on this date
Performance vesting price $8.00 ADS price 30-day average ADS price needed for option vesting
ADS to Ordinary ratio 10 ADSs = 23 Ordinary Shares Representation ratio for NovaBridge Ordinary Shares
Restricted Share Units financial
"The RSUs shall vest over four years, with one-fourth vesting on September 3, 2026"
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
American Depositary Shares financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one American Depositary Shares ("ADS")."
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
30-trading-day weighted average price financial
"the 30-trading-day weighted average price of the Issuer's ADS ... is at or above US$8.00."
Employee Share Option financial
"2025 Employee Share Option (right to buy)"
contingent right financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one American Depositary Shares"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Cao Sean Wuxiong

(Last)(First)(Middle)
C/O NOVABRIDGE BIOSCIENCES
2440 RESEARCH BOULEVARD, SUITE 400

(Street)
ROCKVILLE MARYLAND 20850

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
NovaBridge Biosciences [ NBP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Bus. Development Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Share Units(1)06/22/2026A181,280(2) (3) (3)Ordinary Shares(4)181,280(2)$0181,280(2)D
2025 Employee Share Option (right to buy)$1.53(2)06/22/2026A181,290(2) (5)06/22/2036Ordinary Shares(4)181,290(2)$0181,290(2)D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive one American Depositary Shares ("ADS").
2. Number of underlying securities and exercise price expressed in terms of ADSs.
3. The RSUs shall vest over four years, with one-fourth vesting on September 3, 2026 and the balance vesting ratably over the subsequent 12 quarters on the third day of each third month.
4. The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
5. The option vests, if at all, in eight equal quarterly installments following the date on which the 30-trading-day weighted average price of the Issuer's ADS (based on trading days only) is at or above US$8.00.
/s/ Xi-Yong (Sean) Fu as attorney-in-fact06/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did NovaBridge Biosciences (NBP) grant to Cao Sean Wuxiong?

NovaBridge Biosciences granted Cao Sean Wuxiong 181,290 employee share options and 181,280 restricted share units. Both awards relate to Ordinary Shares represented by American Depositary Shares, providing a mix of performance-based and time-based equity incentives.

What are the key terms of the new stock options reported for NBP?

The new options cover 181,290 underlying Ordinary Shares via ADSs, with an exercise price of $1.53 per ADS and expiration on June 22, 2036. Vesting occurs in eight quarterly installments after the ADS 30-day average price reaches $8.00.

How do the restricted share units for NovaBridge Biosciences (NBP) vest?

The 181,280 RSUs vest over four years. One-fourth vests on September 3, 2026, and the remaining three-fourths vest ratably over the next 12 quarters, on the third day of each third month, providing gradual, time-based vesting.

What does each RSU granted by NovaBridge Biosciences (NBP) represent?

Each restricted stock unit represents a contingent right to receive one American Depositary Share. The filing notes the Ordinary Shares may be represented by ADSs, with 10 ADSs corresponding to 23 Ordinary Shares of NovaBridge Biosciences.

Is the equity grant to NovaBridge Biosciences (NBP) executive a market purchase or compensation?

The transactions are compensation-related grants, not market purchases. They are coded as “A” for grant, award, or other acquisition, with zero transaction price per share, reflecting employee stock options and restricted share units awarded to the executive.